Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...
Already struggling to make headway with its recently launched Alzheimer's drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis (ALS) ...
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The small-molecule PIKfyve inhibitor – called ...
Years ago, when venture capitalist Jon Medved took an interest in backing various health tech startups, he had no idea that one day, he would need them to improve his own quality of life. Israel’s ...
This title is part of a longer publication history. The full run of this journal will be searched. TITLE HISTORY A title history is the publication history of a journal and includes a listing of the ...
FDA cleared the start of a pivotal Phase 3 trial testing pridopidine, an oral therapy for ALS. The study will enroll people with early, rapidly progressive ALS. Earlier subgroup analyses suggested ...
Throughout 2025, ALS News Today delivered readers timely reporting on research breakthroughs, patient advocacy, potential treatments, and diagnostic advances for amyotrophic lateral sclerosis (ALS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback